• 1
    National Institute of Health-National Cancer Institute. Cancer rates and risks. Available at: http:seer.cancer.govpublicationsrateriskindex.html. Accessed January 14, 2004.
  • 2
    Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28(2 Suppl 8):16.
  • 3
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:168992.
  • 4
    Lee SJ, Kwon JH, Jung CW. Erythropoietin response is inadequate in cancer patients receiving chemotherapy. Int J Hematol 2001; 74:41620.
  • 5
    Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21(2 Suppl 3):38.
  • 6
    Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26(4):30311.
  • 7
    Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18:5559.
  • 8
    Ershler WB. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc 2003; 51(3 Suppl):S1820.
  • 9
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:161634.
  • 10
    Ta S. F., Eralp Y, Basaran M, etal Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25(4):3719.
  • 11
    Ludwig H, van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40:2293306.
  • 12
    Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001; 28(2 Suppl 8):549.
  • 13
    Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28(2 Suppl 8):714.
  • 14
    Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14:5119.
  • 15
    Vogelzang NJ, Breitbart W, Cella D, for The Fatigue Coalition Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997; 34(3 Suppl 2):412.
  • 16
    Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:35360.
  • 17
    Curt G, Johnston PG. Cancer fatigue: the way forward. Oncologist 2003; 8(Suppl 1):2730.
  • 18
    Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34(Suppl 2):139.
  • 19
    Yellen SB, Cella D. F., Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:6374.
  • 20
    Vaupel P, Thews O, Höckel M. Tr eatment resistance of solid tumors. Med Oncol 2001; 18:24360.
  • 21
    Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28(2 Suppl 8):3641.
  • 22
    Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000; 46:45966.
  • 23
    Thomas GM. Raising hemoglobin level: an opportunity for increasing survival Oncology 2002; 63(Suppl 2):1928.
  • 24
    van Belle SJ, Cocquyt V. Impact of hemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47:111.
  • 25
    Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:221421.
  • 26
    Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86(8):152836.
  • 27
    Casas F, Viñolas N, Ferrer F, et al. Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:11624.
  • 28
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083107.
  • 29
    National Comprehensive Cancer Network Practice Guidelines in Oncology. Cancer and treatment-related anemia: v.1. 2004. National Comprehensive Cancer Network, Inc., 2004.
  • 30
    O'Shaughnessy J, Vukelja S, Savin M, et al. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res Treat 2002; 76:S138 (Abstract 550).
  • 31
    Crawford J, Robert F, Perry MC, Belani C, Sarokhan B. Prevention of anemia with once weekly epoetin alfa in patients with non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41(Suppl 2):S74 (Abstract O-254).
  • 32
    Hudis CA, Williams D. Early treatment of mild anemia with once-weekly epoetin alfa significantly improves hemoglobin and quality of life in early-stage breast cancer patients during conventional adjuvant chemotherapy. Breast Cancer Res Treat 2003; 82(Suppl 1):S154 (Abstract 639).
  • 33
    Straus DJ, Testa M, Riggs SA, Tulpule A, Sarokhan B. Early treatment with epoetin alfa improves anemia, quality of life, and productivity in patients with hematologic malignancies and mild anemia during chemotherapy. Blood 2003; 102:Abstract 1811.
  • 34
    Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:88895.
  • 35
    Aranesp [prescribing information] Thousand Oaks , CA : Amgen Inc, 2003.
  • 36
    Procrit [prescribing information] Raritan , NJ : Ortho Biotech Products, L.P, 2004.
  • 37
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon J. P. Transfusion medicine. First of two parts–blood transfusion. N Engl J Med 1999; 340:43847.
  • 38
    Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361:1619.
  • 39
    Littlewood TJ, Bajetta E, Nortier J. W., Vercammen E, Rapoport B, for the Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:286574.
  • 40
    Mulcahy L. The erythropoietin receptor. Semin Oncol 2001 28(2 Suppl 8):1923.
  • 41
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(Suppl 1):310.
  • 42
    McKenzie SR, Heifetz LJ, Duh M-S, Piech CT. Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community setting. Blood 2002:Abstract 5591.
  • 43
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003; 25:278196.
  • 44
    Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57:4118.
  • 45
    Zagari M, Wacholtz M, Xiu L. An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-containing chemotherapy. Presented at the European Hematology Association, 2003:Abstract 0177.
  • 46
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:121834.
  • 47
    Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:341225.
  • 48
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhor LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:287582.
  • 49
    Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98:10729.
  • 50
    Witzig TE, Silberstein P. T., Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemia patients with cancer undergoing chemotherapy. J Clin Oncol 2004, in press.
  • 51
    Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving nonplatinum chemotherapy. Br J Cancer 2002; 87:134153.
  • 52
    Fairclough DL, Gagnon DD, Zagari MJ, Marschner N, Dicato M for the Epoetin Alfa Study Group Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Qual Life Res 2003; 12:101327.
  • 53
    Gregor SA, Williams D. Epoetin alfa 60,000 U QW followed by Q2W maintenance dosing corrects anemia and maintains hemoglobin in anemic patients with cancer receiving chemotherapy. Blood 2003; 102:Abstract 4373.
  • 54
    Langer CJ, Williams D. Anemia correction and hemoglobin maintenance with epoetin alfa 60,000 U QW followed by 80,000 U Q3W in anemic patients with cancer receiving chemotherapy. Blood 2003; 102:Abstract 4374.
  • 55
    Shasha D, Williams D. Epoetin alfa 40,000 U once-weekly increases hemoglobin and improves quality of life in anemic patients not receiving chemotherapy or radiotherapy. Blood 2003; 102:Abstract 4375.
  • 56
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9:906.
  • 57
    Prescrire International Epoetin alfa and epoetin beta: treatment of anaemia due to cytotoxic chemotherapy. Prescrire International 2002; 11:3943.
  • 58
    Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002; 20:248694.
  • 59
    Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122:38693.
  • 60
    Littlewood TJ, Schenkel B. An assessment of weekly dosing regimens of recombinant human erythropoietins (rHuEPOs) for anemia correction in a broad range of patients with hematologic malignancies. Eur J Cancer 2003; 1(Suppl 5):S283.
  • 61
    Demetri GD, Glaspy J, Gabrilove J. Hematologic and quality of life benefits of epoetin alfa once weekly vs 3 times weekly in patients with hematologic malignancies. Hematol J 2001; 1(Suppl 1):59 (Abstract 193).
  • 62
    Blayney D. W., Spiridonidis H, Fesen MR, et al. Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: experience in a randomized, open-label study. Proc Am Soc Clin Oncol 2003; 22:747 (Abstract 3003).
  • 63
    Vadhan-Raj S, Schreiber F, Thomas LC, et al. Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients undergoing chemotherapy. Proc Am Soc Clin Oncol 2003; 22:732 (Abstract 2942).
  • 64
    Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized, Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:121120.
  • 65
    Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002; 119:7986.
  • 66
    Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87:26876.
  • 67
    Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003; 23:101S109S.
  • 68
    Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(Suppl 2): S28.
  • 69
    Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21(2 Suppl 3):218.
  • 70
    Quirt I, Robeson C, Lau C. Y. et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19:412634.
  • 71
    Smith Jr RE, Jaiyesiml IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001; 84(Suppl 1):2430.
  • 72
    Auerbach M, Ballard H, Trout R, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:13017.
  • 73
    Hesketh PJ, Arena F, Patel D, et al. Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles. Proc Am Soc Clin Oncol 2003; 22:731 (Abstract 2941).
  • 74
    Moebus V, Kurbacher C, Nitz U, et al. Epoetin alfa prevents anemia and transfusions in patients receiving dose-dense sequential chemotherapy (ETC). Breast Cancer Res Treat 2003; 82(Suppl 1):S153 (Abstract 638).
  • 75
    Barnias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin: a prospective open-label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003; 64:10210.
  • 76
    Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002; 88:1509.
  • 77
    Grote T, Castillo R, Fishkin E, Deleo M. The effect of r-HuEPO in patients with small cell lung cancer (SCLC). Lung Cancer 2003; 41(Suppl 2):S74 (Abstract O-252).
  • 78
    Leyland-Jones B; BEST Investigators and Study Group Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:45960.
  • 79
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:125560.
  • 80
    Food and Drug Administration/Department of Health and Human Services/Oncology Drugs Advisory Committee May 4, 2004 meeting notes. Available at http:www.fda.govohrmsdocketsaccder04.htmlOncologic.Accessed September 3, 2004